2.6  -0.19 (-6.81%)		01-30 16:00
Open: 2.755 High: 2.78 Volume: 700,339		Pre. Close: 2.79 Low: 2.45 Market Cap: 157(M)

Short term
Mid term
Targets	6-month :	3.56	1-year :	4.16
Resists	First :	3.04	Second :	3.56
Pivot price	2.09
Supports	First :	2.19	Second :	1.66
MAs	MA(5) :	2.59	MA(20) :	2.06
	MA(100) :	1.9	MA(250) :	1.5
MACD	MACD :	0.1	Signal :	0
%K %D	K(14,3) :	77	D(3) :	73.8
RSI	RSI(14): 66.4
52-week	High :	3.04	Low :	0.85

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ABOS ] has closed below upper band by 18.1%. Bollinger Bands are 165.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	2.78 - 2.8	2.8 - 2.81
Low:	2.42 - 2.43	2.43 - 2.45
Close:	2.57 - 2.6	2.6 - 2.62

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Sat, 31 Jan 2026
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Lowered to Sell at Wall Street Zen - MarketBeat

Wed, 28 Jan 2026
Healthcare Stocks Surge in After-Hours Trading - Intellectia AI

Wed, 28 Jan 2026
While Institutions Invested in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Benefited From Last Week's 46% Gain, Private Equity Firms Stood to Gain the Most - 富途牛牛

Tue, 27 Jan 2026
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research - MarketBeat

Tue, 27 Jan 2026
Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative? - Sahm

Tue, 27 Jan 2026
Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	61 (M)
Shares Float	35 (M)
Held by Insiders	6.8 (%)
Held by Institutions	64.7 (%)
Shares Short	554 (K)
Shares Short P.Month	575 (K)

EPS	-2.22
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.53
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-42.3 %
Return on Equity (ttm)	-86 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-1.97
Sales Per Share	0
EBITDA (p.s.)	-2.29
Qtrly Earnings Growth	0 %
Operating Cash Flow	-124 (M)
Levered Free Cash Flow	-79 (M)

PE Ratio	-1.18
PEG Ratio	0
Price to Book value	1.68
Price to Sales	0
Price to Cash Flow	-1.28

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.